OCHSNER OUTCOMES - Ochsner Health System...Ochsner Health System ... OUTCOMES DIGESTIVE DISEASES 7...

PU

BLIS

HE

D2017

OCHSNEROUTCOMES Digestive Diseases

Patient referrals, transfers and consults are critically important, and we want to make it easy for referring providers and their staff. To refer your patient for a clinic appointment, call our Clinic Concierge at 855.312.4190.

Warner L. ThomasPresident &

Chief Executive Officer Ochsner Health System

Ochsner’s longstanding tradition of bringing physicians together to improve health outcomes continues today. Our goals are to work together with our referring providers to serve the needs of patients and to provide coordinated treatment through partnerships that put patients first. We have automated physician-to-physician patient care summaries for hospital encounters and enhanced the patient experience by giving patients the ability to schedule appointments online.

Close coordination and collaboration begin with transparency and access to the data you need to make informed decisions when advising your patients about care options. OchsnerOutcomes, a compilation of clinical data, represents only part of our efforts to better define the quality of Ochsner’s care and to share that information with you.

Trusted, independent organizations give the highest marks to Ochsner’s quality. Ochsner Medical Center was the only healthcare institution in Louisiana, Mississippi and Arkansas to receive national rankings in four adult specialties from U.S. News & World Report for 2017–2018. Ochsner Hospital for Children has been ranked among the top 50 children’s hospitals in the country for Cardiology and Heart Surgery in the 2017–2018 U.S. News & World Report Best Children’s Hospitals rankings, making it the only nationally ranked children’s hospital in Louisiana.

Additionally, CareChex® named Ochsner Medical Center, Ochsner Baptist and Ochsner Medical Center – West Bank Campus among the top 10% in the nation in Medical Excellence for 16 different specialties. Ochsner was also named #1 in the nation in Medical Excellence for Organ Transplants and, for the fifth year in a row, #1 in the nation in Medical Excellence and Patient Safety for Liver Transplant.

Ochsner is expanding its already robust research program with two new partnerships. The first, with TGen, brings early-phase cancer clinical trials to the region. The second, with TriNetX, an international data research network, will allow Ochsner clinicians to have the opportunity to provide new therapies to their patients sooner, as well as provide our researchers access to new tools with which to analyze data on our own patients and refine treatments.

Ochsner Multi-Organ Transplant Institute is one of 19 transplant hospitals in the United States to participate in the initial pilot phase of the Collaborative Innovation and Improvement Network (COIIN) project, a three-year study by the United Network for Organ Sharing (UNOS) intended to increase transplantation, with a particular focus on utilization of deceased donor kidneys.

Ochsner consistently earns the respect of independent evaluators. We do not rest on these achievements, but use them as a benchmark to continuously improve. We will continue to share the data you need to care for your patients, provide services you may not have in your community and develop the collaborative relationships essential to ensuring the best outcomes for every patient, every time.

Robert I. Hart, MDExecutive Vice President &

Chief Medical OfficerOchsner Health System

Table of ContentsLetter from the Chairmen . . . . . . . . . . . . . . . . . . . . . . 6

Digestive Disease Program . . . . . . . . . . . . . . . . . . . . . 7

Procedural Overview . . . . . . . . . . . . . . . . . . . . . . . . . . 9

Inpatient Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . 14

Colon and Rectal Surgery . . . . . . . . . . . . . . . . . . . . . . 18

Advanced Endoscopy Program . . . . . . . . . . . . . . . . . . 22

Fecal Microbiota Transplantation . . . . . . . . . . . . . . . . . 31

Hepatology Overview . . . . . . . . . . . . . . . . . . . . . . . . . 32

Patient Experience . . . . . . . . . . . . . . . . . . . . . . . . . . . 39

Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43

Publications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51

Physician Team . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53

About Ochsner Health System . . . . . . . . . . . . . . . . . . 54

Nigel Girgrah, MD, PhDChairman, Department of

Gastroenterology and Hepatology; Medical Director, Multi-Organ

Transplant Institute

Charles B. Whitlow, MD, FACS, FASCRSChairman, Department of Colon

and Rectal Surgery

Letter from the ChairmenOchsner’s Digestive Disease Program is rated among the top programs in the nation. U.S. News & World Report ranked Ochsner #22 in the Nation for Gastroenterology & GI Surgery in 2017. Our quality is a direct reflection of our caring, experienced and dedicated team who work hard every day to produce excellent patient outcomes.

Ochsner’s comprehensive service offerings within the Digestive Disease Program are unmatched in the region. Ochsner provides patients with a fully coordinated, multidisciplinary program to treat even the most complex gastrointestinal and colorectal diseases. As one of the few hospitals in the United States to fully integrate its Gastroenterology and Colon and Rectal Surgery departments, Ochsner offers the widest spectrum of diagnostic and treatment modalities for patients with esophageal disorders, pancreatobiliary diseases, inflammatory bowel disease, lower intestinal bleeding, motility disorders and colorectal cancer. In addition, we offer nationally recognized care for chronic and end-stage liver disease. CareChex® ranked Ochsner Medical Center #1 in the Nation in Medical Excellence and Patient Safety for Liver Transplants in 2017, for the fifth year in a row. As the only physiology testing lab in the region, Ochsner also offers a comprehensive array of diagnostic and screening services.

Our Colon and Rectal Surgery team has a wealth of experience and expertise, with members actively involved in the American Society of Colon and Rectal Surgery. The department has employed six past presidents of the American Society of Colon and Rectal Surgeons and five past presidents of the American Board of Colon and Rectal Surgery. Members have edited and contributed to numerous textbooks and original journal publications in the specialty and are internationally recognized experts. Our surgeons routinely use advanced surgical technologies such as laparoscopy and robotics, as well as multimodal perioperative pain control, to improve patient outcomes. And our minimally invasive transanal surgery and advanced colonoscopic polypectomy procedures permit the removal of many precancerous lesions without radical resection.

Additionally, the department has a robust Research Institute that is actively involved in colorectal cancer clinical trials and translational research involving metastatic colorectal cancer. We look forward to sharing our outcomes with you.

Digestive Disease ProgramEach year, millions of Americans suffer from some form of digestive disorder, ranging from acid reflux and irritable bowel diseases to life-threatening colon, rectal, esophageal or pancreatic cancers. These disorders can profoundly affect the health and lives of our patients and their families.

Ochsner Digestive Disease Program is a multidisciplinary practice specializing in the prevention, diagnosis and treatment of gastrointestinal and liver disease. Our team of physicians has dedicated their decades of combined clinical experience to serving patients and their families.

The treatment teams and physicians provide excellent patient care, resulting in superb outcomes that are benchmarked against the industry’s top healthcare systems. The program’s inpatient and outpatient endoscopic facilities specialize in the prevention, diagnosis and treatment of various gastrointestinal diseases.

Our goal is to provide the safest, highest quality care to every patient, every time.

In 2016, Ochsner transitioned from ICD 9 to 10 (International Statistical Classification of Diseases and Related Health Problems). The 10th edition allows for greater accuracy with the addition of more than 14,000 new diagnostic codes and sub-classifications. While this tool permits greater specificity, the additional classifications have resulted in outcomes metrics that may appear inconsistent from 2015 to 2016.

6

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

7

DIG

ESTIV

E DISEA

SE PROG

RA

M

Average Colonoscopy Withdrawal Time (in Minutes) Ochsner Medical Center, 2016

Total Colonoscopy Procedures Ochsner Medical Center, 2014–2016

Procedural OverviewIncreasing colonoscopy withdrawal time has previously been shown to be associated with increasing adenoma detection rate (ADR).

ADR is the percentage of adenomatous (precancerous) polyps that physicians detect per screening colonoscopy, with the benchmarks being >25% in males and >15% in females. Withdrawal time is the time spent by the physician viewing the colon from the cecum (end of the colon) to the rectum, searching for polyps with the intent to remove them.

A withdrawal time >6 minutes has been shown to be a reliable indicator of colon polyp detection. Cecal intubation is indicated by photographs taken of the ileocecal valve and the terminal ileum, indicating that the physician has viewed the colon in its entirety for that exam.

Digestive Disease Unique Patients Ochsner Medical Center, 2014–2016

201620152014

8,1277,780 7,942

201620152014

8,3189,167 8,905

Includes the average withdrawal duration for screening and surveillance colonoscopies without intervention.

National BenchmarkOchsner

10.9

6

8

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

9

PROC

EDU

RA

L OV

ERVIEW

Adenoma Detection Rate in Men Ochsner Medical Center, 2016

Percentage of patients age 50 and over undergoing screening colonoscopy with a finding of at least one adenomatous polyp.

Male GoalOchsner

44.7%

25.0%

Adenoma Detection Rate in Women Ochsner Medical Center, 2016

Percentage of patients age 50 and over undergoing screening colonoscopy with a finding of at least one adenomatous polyp.

Female GoalOchsner

33.5%

15.0%

Adenomatous Polyp

Ileocecal Valve

Success is defined by reaching the cecum, ileum, terminal ileum or ileocecal valve. Exams that were aborted or where the patient has complex surgically altered anatomy (such as a surgical stoma) are not included.

Cecal Intubation Rate Ochsner Medical Center, 2016

DecNovOctSepAugJulJunMayAprMarFebJan

98.9%98.9%

99.1%

99.8% 99.8% 100.0%

99.1%99.4%

99.9%

98.3%

98.8% 98.9%

10

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

11

PROC

EDU

RA

L OV

ERVIEW

Total EGD* Procedures Ochsner Medical Center, 2014–2016 *Esophagogastroduodenoscopy

Total Endoscopy Procedures Ochsner Medical Center, 2014–2016

Ochsner prides itself in maintaining the highest standards in infection prevention, adhering to national patient safety goals and maintaining clinical competencies that are supported by national recommendations for all staff. Our physicians maintain quality metrics for colon cancer screening that exceed national guidelines related to adenoma detection rate, withdrawal time and cecal intubation rates.

The Endoscopy Lab serves both inpatients and outpatients needing preventive screening and diagnostic procedures. Patients and their families are welcomed by a multidisciplinary team of physicians, nurses, nurse anesthetists and technicians. It is our goal to provide safe, high-quality, empathetic care to those we serve.

0%

4000%

8000%

12000%

16000%

20000%

201620152014

16,639 16,416

17,667

0%

1600%

3200%

4800%

6400%

8000%

201620152014

5,7396,024

6,255

12

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

13

PROC

EDU

RA

L OV

ERVIEW

Inpatient OverviewThe quality of care provided by the Digestive Disease Center is reflected in the lower-than-expected mortality rate in patients with gastrointestinal medical diagnoses.

Digestive Diseases Case Volume Ochsner Medical Center, 2014–2016

201620152014

4,9885,196 5,158

14

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

15

INPA

TIENT O

VERV

IEW

Gastroenterology Risk-Adjusted Mortality Index (RAMI) Ochsner Medical Center, 2014–2016

Methodology and Source: IBM Watson Health / Truven Care Discovery

Compare Group: Average of All Hospitals Nationwide

Adult Hospital Inpatients Only

0.80

201620152014

0.69

1.01

RAMI National Average




ECRI National Average

Gastroenterology Expected Complication Rate Index (ECRI) Ochsner Medical Center, 2014–2016

201620152014

1.00

0.43

0.700.58

Gastroenterology Average Length of Stay (in Days) Ochsner Medical Center, 2014–2016




Ochsner Average National Average

201620152014

4.44.1

4.34.0

4.33.9

16

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

17

INPA

TIENT O

VERV

IEW

Colon and Rectal Surgery Case Volume Ochsner Medical Center, 2014–2016

Colon and Rectal SurgeryThe Department of Colon and Rectal Surgery is composed of a talented and dedicated group of surgeons and advanced practice providers and includes six past presidents of the American Society of Colon and Rectal Surgeons and five past presidents of the American Board of Colon and Rectal Surgery.

Members of the department have edited and contributed to numerous textbooks and original journal publications in the specialty and are internationally recognized experts. U.S. News & World Report ranked the GI surgery program at Ochsner Medical Center as one of the top 25 programs in the nation. The team of experienced and highly skilled physicians evaluates and treats diseases and conditions of the anus, rectum and colon and strives to combine innovative treatments with personal and individual care. The program is supported by advanced techniques and state-of-the-art technology.

The Department of Colon and Rectal Surgery specializes in the surgical treatment of anal, rectal and colon cancers. The multidisciplinary team approach maximizes sphincter

preservation and survival. The team has performed more than 575 sphincter-sparing procedures. Advanced operative technology such as laparoscopy and robotics, as well as multimodal perioperative pain control, are routinely used to improve patient outcomes. Minimally invasive transanal surgery and advanced colonoscopic polypectomy allow many precancerous lesions to be removed without radical resection. Additionally, the department is actively involved in colorectal cancer clinical trials and translational research involving metastatic colorectal cancer.

Unique and Innovative Procedures:

• TAMIS (Transanal Minimally Invasive Surgery) for excision of rectal cancer and polyps

• Continent Ileostomy

• Sacral Nerve Stimulation for fecal incontinence

• Colonic Stenting

• Ileoanal Pouches

201620152014

999 1,040

1,182

Relative 5-Year Colon Cancer Survival Rates by Staging Ochsner Medical Center, 2003–2015

* Surveillance, Epidemiology, and End Results program from the National Cancer Institute

Ochsner Medical Center, Adult Cancer Patients (18 years +), 2003–2015. Ochsner N: All Stages = 1,230; Localized = 351; Regional = 310; Distant = 249. SEER Cancer Statistics 2007–2013. SEER N: All Stages = 144,817; Localized = 55,030; Regional = 52,134; Distant = 31,860.

Ochsner SEER* Survival

DistantRegionalLocalizedAll Stages

73.6%

64.1%

99.0%

90.7%

81.0%

71.7%

23.8%

13.6%

18

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

19

CO

LON

AN

D REC

TAL SU

RGERY

Colorectal Surgical Site Infection Rate Ochsner Medical Center, 2013–2016

Ochsner Rate National Benchmark

0.0%

12.5%

25.0%

Q4 ’16Q3 ’16Q2 ’16Q1 ’16Q4 ’15Q3 ’15Q2 ’15Q1 ’15Q4 ’14Q3 ’14Q2 ’14Q1 ’14Q4 ’13Q3 ’13

9.2%

12.9%

11.4%

7.9%

12.5%

9.4%

9.9%

8.3%7.2%

8.4%

5.7%

9.2%

6.7% 7.3% 7.6%

Colorectal Surgery Risk-Adjusted Mortality Index (RAMI) Ochsner Medical Center, 2014–2016




1.04

201620152014

1.14

0.36

RAMI National Average




ECRI National Average

Colorectal Surgery Expected Complication Rate Index (ECRI) Ochsner Medical Center, 2014–2016

201620152014

1.00

0.47 0.47

0.93

Colorectal Surgery Average Length of Stay (in Days) Ochsner Medical Center, 2014–2016




Ochsner Average National Average

201620152014

9.4

8.27.8 7.8

6.5

7.5

20

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

21

CO

LON

AN

D REC

TAL SU

RGERY

Advanced Endoscopy Program Extensive experience, premier skills, a multidisciplinary team approach, the latest technological advances and innovative research propel Ochsner’s Advanced Endoscopy Program to national leadership in the evaluation and treatment of various complex luminal, pancreatic and biliary diseases. The Advanced Endoscopy Team comprises three full-time interventional endoscopists along with nurses and assistants who are trained and experienced in and dedicated to advanced endoscopy procedures. This team delivers the highest level of patient care with a keen focus on superb outcomes and patient safety.

Endoscopic Ultrasound Volume Ochsner Medical Center, 2014–2016

Conditions we evaluate and treat:

• Barrett’s esophagus

• Esophageal/UGI tract/anastomotic/colonic strictures (benign, malignant and refractory)

• GI tract fistulas, leaks and perforations

• GI tract neoplasms: advanced diagnostics/ detection/staging/local therapy

• Gastric and esophagogastric varices

• Gastric antral vascular ectasia (GAVE)

• Small bowel and obscure GI bleeding

• Biliary tract stones

• Biliary tract strictures: benign/postoperative/ malignant/indeterminate

• Bile leaks

• Pancreatic cysts

• Acute, recurrent and chronic pancreatitis

• Pancreatic and biliary tract cancers

Procedures we perform:

• Diagnostic endoscopic ultrasound (EUS): tumor detection/ staging/tissue sampling

• Interventional endoscopic ultrasound: celiac block-neurolysis/pseudocyst drainage and necrosectomy/fiducial placement/biliary or pancreatic duct drainage/liver biopsy/gastric varices obliteration

• ERCP: includes ductoscopy/intraductal lithotripsy/ endomicroscopy/altered anatomy procedures

• Single-session EUS/ERCP

• Endoscopic mucosal resection (EMR) / endoscopic submucosal dissection (ESD)

• Endoscopic ablation: luminal/biliary

• Endomicroscopy: luminal tract/biliary/pancreas cyst

• Stent placement: luminal tract/pancreatic/biliary

• Endoscopic suturing/clipping

• Deep enteroscopy (e.g., double balloon)

0%

600%

1200%

1800%

2400%

3000%

201620152014

1,121971

1,563

22

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

23

AD

VA

NC

ED EN

DO

SCO

PY PRO

GR

AM

Grades of Difficulty of Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures*

Grade Procedure

1 Deep cannulation of duct of interest, main papilla or sampling

Biliary stent removal or exchange

2 Biliary stone extraction <10mm

Treatment of biliary leaks

Treatment of extrahepatic strictures (benign or malignant)

Placement of prophylactic pancreatic stents

3 Biliary stone extraction >10mm

Minor papilla cannulation in divisum and therapy

Removal of internally migrated biliary stents

Intraductal imaging, biopsy, or fine-needle aspiration

Management of acute or recurrent pancreatitis

Treatment of pancreatic strictures

Removal of pancreatic stones that are mobile and <5mm

Treatment of hilar tumors

Treatment of benign biliary strictures, hilum and above

Management of suspected sphincter of Oddi dysfunction (with or without manometry)

4 Removal of internally migrated pancreatic stents

Intraductal image–guided therapy (e.g., photodynamic therapy)

Removal of pancreatic stones that are impacted and/or >5mm

Removal of intrahepatic stones

Pseudocyst drainage or necrosectomy

Ampullectomy

ERCP after a Whipple procedure or Roux-en-Y bariatric surgery

* One grade should be added (for a maximum grade of 4) for procedures performed after normal working hours, in children under 3 years of age, in post–Billroth II gastrectomy patients, or for procedures that have previously failed.

Adapted from Cotton PB, et al. Gastrointest Endosc. 2011; 73: 868–874.

ERCP Volume Ochsner Medical Center, 2014–2016

201620152014

730 734

843

Endoscopic Retrograde Cholangiopancreatography (ERCP) ASGE Complexity Level Ochsner Medical Center, 2016

Grade 1 Grade 2 Grade 3 Grade 4

62%

11%

7%

20%

2524

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

SA

DV

AN

CED

END

OSC

OPY

PROG

RA

M

Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection Volume (Upper and Lower GI Tract) Ochsner Medical Center, 2014–2016

201620152014

77

91100

ERCP Quality Metrics Ochsner Medical Center, 2016

Extraction of Stones <10mmStents Placed / Stricture Below BifurcationNative Papilla Cannulation

97% 99% 98%

26

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

27

AD

VA

NC

ED EN

DO

SCO

PY PRO

GR

AM

Barrett’s Esophagus Thermal Ablation Volume Ochsner Medical Center, 2014–2016

Device-Assisted Enteroscopy Volume Ochsner Medical Center, 2014–2016

201620152014

33

67 64

201620152014

42

74

38

Esophagus

Stomach

Small Bowel

Ochsner helped pioneer the endoscopic diagnosis and management of digestive disease. Each year, more than 17,000 endoscopic procedures, such as colonoscopy and upper endoscopy, are performed in our endoscopy centers.

28

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

29

AD

VA

NC

ED EN

DO

SCO

PY PRO

GR

AM

Fecal Microbiota TransplantationFecal microbiota transplantation is a new treatment that has been shown to be 90 percent effective for treating Clostridium difficile infections.

Ochsner has capitalized on this interest to lead the battle against the epidemic of C. difficile, a bacterial infection that causes half a million illnesses a year in the United States. We have partnered with Open Biome, the first stool bank in the country, to offer safe and effective fecal transplants for patients who suffer from severe or recurrent C. difficile infections. Not only does this partnership reduce the need to find a stool donor, but it also allows us to treat patients

the very next day after meeting them. In addition, we have partnered with Rebiotix® in the quest to develop the first widely available biologic therapy against the C. difficile infection. Though it’s still in clinical trials, Rebiotix has had a high success rate for our fecal transplant patients. Finally, we are hoping to harness the power of the human microbiome to find cures for other gastrointestinal illnesses, such as ulcerative colitis, through active clinical trials.

Fecal Transplant Volume Ochsner Medical Center, 2014–2016

0%

10%

20%

30%

40%

50%

201620152014

3840

28

30

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

31

FECA

L MIC

ROBIO

TA TR

AN

SPLAN

TATIO

N

Hepatology Overview Hepatology services at Ochsner continue to expand rapidly. We have five full-time hepatologists and a team of nurse practitioners, physician assistants, nurses and medical assistants.

We offer same-day appointments for patients with all liver conditions at all levels of severity, including liver cirrhosis and liver transplantation. In 2017, CareChex® ranked Ochsner Medical Center #1 in the Nation in Medical Excellence and Patient Safety for liver transplants for the fifth year in a row. Our liver transplant referral volume and the number of transfers to our hospital from other centers continue to rise yearly. We now take complex referrals from multiple regional and national centers.

Our unique multidisciplinary approach ensures that all patients receive the best quality of care based on current available evidence according to national and international guidelines. The specialized

hepatitis C virus (HCV) treatment clinic treats patients with chronic HCV infections using some of the most technologically advanced treatments available. The HCV team consists of three physician assistants, two registered nurses, one licensed practical nurse and an in-house PharmD and has extensive experience in the management of such patients. In addition to using all the currently approved HCV treatments, the team participates in several clinical trials that allow some of our patients to take advantage of experimental therapies not available elsewhere.

The hepatology team has all the technological innovations at their disposal to make the best treatment

recommendations for their patients. Detailed abdominal ultrasound, computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning are all available through the Radiology department. In addition, we now offer elastography as a noninvasive method of assessing liver fibrosis without a liver biopsy. Transjugular portosystemic shunts and locoregional therapy for hepatocellular cancer (transarterial chemoembolization, radiofrequency ablation, yttrium-90 radioembolization) are also available. Our unique relationship with the Multi-Organ Transplant Institute allows us unique access to transplant and hepatobiliary surgery for those patients who need it.

In 2017, CareChex® ranked Ochsner Medical Center #1 in the Nation in Medical Excellence and Patient Safety for liver transplants for the fifth year in a row.

32

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

33

HEPA

TOLO

GY

OV

ERVIEW

The advent of exciting new antiviral therapies and noninvasive measurements of liver fibrosis has been associated with an increase in hepatitis C clinic visits.

We have adopted a patient-centered approach to liver transplant assessment, with many patients being able to complete their evaluations for a liver transplant in one and a half days. Referrals for liver transplants have steadily increased, and Ochsner has

performed the most liver transplants compared to any other program in the United States. CareChex® ranked Ochsner Medical Center #1 in the nation for medical excellence for liver transplants.

Hepatitis C Clinic Visit Volume Ochsner Medical Center, 2014–2016

Liver Transplant Referrals Ochsner Medical Center, 2014–2016

201620152014

1,216 1,222

1,769

201620152014

760

862807

Liver Transplant Volume Ochsner Medical Center, 2000–2016

0%

80%

160%

240%

320%

400%

20162015201420132012201120102009200820072006200520042003200220012000

5

2

4563 58

98 95 9278

9990

120 123 125

168 166185

228212

10

38

4

3

3

3

3

5

4

8

3

6

3

3

91 2 1

1

1

Adult Liver – Cadaveric Whole Adult Liver – Live Donors or Split Pediatric Liver – Whole and Split

34

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

35

HEPA

TOLO

GY

OV

ERVIEW

For patients with advanced liver disease in need of a liver transplant, wait time for transplantation is crucial. Ochsner’s liver transplant program has among the very shortest wait times in the country for liver transplant as measured by time to transplant from wait-listing as well as from referral to our program.

Median Wait Time to Liver Transplant (in Months) Ochsner Medical Center, 7/1/2010 – 12/31/2015

United StatesRegion 3Ochsner

2.1

3.9

15.2

Region 3: LA, MS, AR, AL, FL, GA, Puerto Rico

United States: All liver transplant centers in the U.S. including Ochsner.

The data reported here were prepared by the Scientific Registry of Transplant Recipients (SRTR) under contract with the Health Resources and Services Administration (HRSA). Based on data available as of October 31, 2016. Publication date December 2016.

3736

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

SH

EPATO

LOG

Y O

VERV

IEW

Patient ExperienceAt Ochsner, we serve patients from all 50 states and 80 countries, and we are increasingly recognized for our abiding commitment to state-of-the-art care. At the center of everything we do is the patient. Our goal is to continue to achieve excellence in our commitment to saving and changing lives, one patient at a time.

Gastroenterology – Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) Ochsner Medical Center, 2016

0%

50%

100%

Care Coordination

Access to Care

Office Staff Quality

Physician Communication

Recommend this Provider Office

91.6 90.794.1 92.5

95.3 93.1

79.5 79.5

73.7

81.3

CG CAHPS information was based on provider specialty with a visit date between 1/1/2016 – 12/31/2016; adjusted per Press Ganey methodology for eSurvey.

Ochsner Average Press Ganey Average

38

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

39

PATIEN

T EXPERIEN

CE

Colon and Rectal Surgery – Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Ochsner Medical Center, 2016

Colon and Rectal Surgery – Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) Ochsner Medical Center, 2016

0%

50%

100%

Care Coordination

Access to Care

Office Staff Quality

Physician Communication

Recommend this Provider Office

94.190.7 92.7 92.5

95.6

87.0

73.1

93.1

79.5

73.7

0%

50%

100%

Care Transitions

Discharge Information

Comm about Medicines

Pain Management

Hospital Environment

Comm with Doctors

Response of Hosp Staff

Comm with Nurses

Overall Hospital Rating

81.7

73.1

82.2 80.3

58.5

67.9

92.7

81.3

67.2 67.6

78.8

71.167.4

64.9

94.6

87.6

65.5

54.1

CG CAHPS information was based on provider specialty with a visit date between 1/1/2016 – 12/31/2016; adjusted per Press Ganey methodology for eSurvey.

The HCAHPS data was based on the specialty field in infoEdge for patients with a discharge date between 1/1/2016 – 12/31/2016. The specialty field is based on the DRG that is on the record and the CMS specialty group that is tied to the DRG.



40

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

41

PATIEN

T EXPERIEN

CE

Colon & Rectal Surgery Open Clinical Trials

Study Title and Staff Study Title Principal Investigator

Retrospective Chart Review: The Proximal Migration of Colon Cancer – Are more colon cancers being detected on the right side of the colon?

David Margolin

Prospective Randomized Study of Elective Colon and Rectal Surgery with or without Mechanical Bowel Preparation – Is bowel prep necessary prior to colon surgery?

David Margolin

Lower Gastrointestinal Hemorrhage: Prospective Database – Using the information collected in this database, we plan to address questions regarding the accuracy and proper utilization of diagnostic radiographic and endoscopic modalities in the management of this condition

David Margolin

Fecal Incontinence: Prospective Database – Using the information collected in this database, we plan to address questions regarding the accuracy and proper utilization of diagnostic modalities in the management of this condition

David Margolin

Diverticulitis: Prospective Database – Using the information collected, we plan to address questions regarding the accuracy and proper utilization of diagnostic modalities in the management of this condition

David Margolin

Rectal Cancer: Prospective Database – Using the information collected, we plan to address questions regarding the accuracy and proper utilization of diagnostic modalities in the management of this disease

David Margolin

Retrospective Chart Review: Factors in Stoma Reversal in Hartmann’s Procedure Patients – Attempts to determine the factors why or why not a stoma is reversed in patients who undergo a Hartmann’s procedure

David Margolin

Retrospective Chart Review: The Natural History of Patients After Endoscopic Removal of One Centimeter Colonic Polyps – Study the natural history of the subset of patients who had relatively small polyps to determine at what rate these patients develop further polyps, and if any patient characteristics influence that rate

David Margolin

Retrospective Chart Review: Endoscopic Screening and Surveillance of the Colon and Rectum in Solid Organ Transplant Recipients – Is there an increased rate of colorectal cancer among patients who are on long term immunosuppression therapy?

David Margolin

Research

43

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

42

RESEARC

H


Retrospective Chart Review: Fecal Impaction: Natural History and Therapeutic Outcomes – Attempts to determine etiologic factors, therapeutic outcomes, and recurrence rates of fecal impaction

David Margolin

Retrospective Chart Review: Is There a Role for Surgery in Stage IV Colorectal Cancer – Assesses the impact that surgical resection has on the length of survival compared to no resection at all and examines factors that may make a difference in surgical outcome

David Margolin

Retrospective Chart Review: Outcomes of Patients with Lower Gastrointestinal Bleed Undergoing Tagged-RBC Studies and Subsequent Mesenteric Angiography – Detects trends in the interventions required for cessation of bleeding, short and long term recurrences of bleeding and long-term follow-up of complications or sequelae of their treatment

David Margolin

Retrospective Chart Review: A Review of Patients Who Underwent Colonoscopy While Taking Anticoagulation Medications – Determining bleeding or thrombotic complications for patients who had a colonoscopy and were on or off anticoagulation therapy

David Margolin

Retrospective Chart Review: The Natural History of T1 Carcinoma of the Colon – A review of patients who have had T1 cancer to determine if there is a correlation between tissue depth, recurrence rates and survival

David Margolin

Z6051 – A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer – Sponsor: Alliance

David Margolin

Retrospective Chart Review: Perianal Abscess Drainage Using Catheters – Looks for trends in the length of catheter drainage, fistula formation, abscess healing, and evidence of recurrence to help guide the creation of a prospective randomized trial

David Margolin

Understanding the Microenvironment of Stem Cells in Colon Cancer – Uses patient acquired tissue and blood samples to identify biomarkers for testing to both confirm a correlation between the presence at diagnosis and clinical outcome and additionally to find ways to eliminate the cancer stem cells

David Margolin

Retrospective Chart Review: Time to Closure of Temporary Ileostomies in Ulcerative Colitis Patients – A comparison of the complication rates and time to stoma closure at Ochsner to rates published in literature

Charles Whitlow

P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer – Sponsor: NSABP David Margolin


Retrospective Chart Review: Parastomal Hernias: Incidence and Management – compares the incidence and treatment of parastomal hernias to those at other institutions

David Beck

Retrospective Chart Review: Colorectal Cancer Tumor Markers and the Relationship to Recurrence and Outcomes – Attempt to correlate recurrence rates and outcomes with tumor markers from historical tissue samples

David Margolin

Retrospective Chart Review: Initial Colonoscopies After Colon Cancer Resection for Cure: What Do We Find – An investigation to examine trends in colonoscopies 1 year after colon cancer resection

David Margolin

Retrospective Chart Review: Quality Metrics for Colonoscopy – Analysis of patients that underwent colonoscopies by the colon rectal surgeons to evaluate if cecal intubation is a quality metric for colonoscopy

David Margolin

Retrospective Outcomes Study of the LIFT Procedure – Evaluates the outcomes of the simplified LIFT procedure

David Margolin

Retrospective Chart Review: Loop Ileostomy – Examines the complications and benefits associated with ileostomy creation and closure

David Margolin

Retrospective Chart Review: Identification of Patients at Risk of Lynch Syndrome among a Cohort of Colorectal Cancer Patients – Aim of this study is to assess whether documentation of hereditary risk was improved through family history documentation, we hypothesize that improved documentation, if present, will lead to further tumor and patient testing for Lynch syndrome

David Margolin

Retrospective Chart Review: Abdominoperineal Resection – Examines the diagnosis and associated outcomes of these procedures

David Margolin

Retrospective Chart Review: Hemorrhoidal Treatment by Rubber Band Ligation in Patients Taking Clopidogrel – Study to demonstrate the safety of this procedure in patients taking clopidogrel

David Margolin

Retrospective Chart Review: Evaluating the Safety of Hot vs. Cold Endoscopic Polypectomies – Examines the complication rates, admission rates and cancer recurrence in hot and cold polypectomies

Charles Whitlow

A Single-Blind, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® as an Adjunct to Gastrointestinal Anastomosis Techniques – Sponsor: Ethicon

David Beck

44

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

45

RESEARC

H


Phase 3 Study of Efficacy and Safety of Topical E-101 Solution to Prevent Incisional Infections among Colorectal Surgery Patients – Sponsor: Excited States, LLC

David Margolin

Retrospective Chart Review: Ileoanal Pouch Outcomes Study – Determine the outcomes of our pouch patients for the previous 15 years, looking for trends within our practice

David Beck

Ligation of the Intersphincteric Fistula Tract with Tissue Graft Placement for Treatment of Persistent Transsphincteric Anal Fistula – Sponsor: Cook, Inc

Charles Whitlow

Retrospective Chart Review: A Review of Rectal Cancers – Evaluates all patients diagnosed or treated for rectal cancer within the Ochsner Health System

David Beck

Retrospective Chart Review: A Registry and Review of Ileopouch Anal Anastomosis – Evaluates and identify trends in patients with ileopouch anal anastomosis

David Margolin

Retrospective Chart Review: Ileal Pouch Anal Anastomosis and Pregnancy – Evaluates possible factors impacting pouch function after vaginal delivery

David Margolin

A Prospective, Multicenter Registry for Patients with Short Bowel Syndrome – Sponsor: NPS Pharmaceuticals

David Vargas

Retrospective Chart Review: Natural History of Polyps Less than 6 mm – Studies the natural history of adenomatous polyps with stratification for patient age to determine at what rate additional polyps develop and if any patient characteristics influence that rate and risk of invasive carcinoma

David Margolin

Retrospective Chart Review: Polypectomy Outcomes in Screening Colonoscopy – Our hypothesis that polypectomy rates are not absolutely indicative of adenoma detection rates and frequent colonoscopies expose patients to unneeded interventions and increased risk for post-polypectomy complications

David Margolin

A Randomized, Controlled, Parallel, Multicenter Study Assessing Perfusion Outcomes with PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection – Sponsor: NOVADAQ

David Margolin

Retrospective Chart Review: Fibromyalgia and Bowel Disorders – Examines any correlation between patients diagnosed with fibromyalgia and bowel disorders

David Margolin

Retrospective Chart Review: Review of Patients Undergoing Colonoscopy while on Anti-Thrombotic Agents – Bleeding and clotting events in the first 60 days following the procedure will be tracked

David Margolin


Cleancision Intraoperative Contamination prevention Study (CIRCE Study) – An Evaluation of the Safety and Efficacy of the CleanCision Wound Retraction and Protection System in Protecting Surgical Incisions from Intraoperative Contamination When Used during Colorectal Surgery – Sponsor: Prescient Surgical

David Margolin

Retrospective Chart Review: The Ochsner Experience with Urinary Bladder Matrix in the Treatment of Complex Fistula in Ano – Evaluates Ochsner’s experience in treating complex fistula in ano disease with urinary bladder matrix

David Margolin

Retrospective Chart Review: Morbidity and Long-Term Mortality Associated with Ileostomy Closure in Rectal Cancer Patients Before and After Adjuvant Therapy – Examines if there is a difference in the 30-day morbidity and or 5-year survival in patients who have their diverting loop ileostomy closed before vs. after adjuvant chemotherapy

David Beck

Retrospective Chart Review: Evaluation of the Current Recommendations on Repeat Colonoscopy for Colorectal Cancer Screening – Are the current guidelines and recommendations for colonoscopy surveillance effective in screening for colorectal adenomas and adenocarcinomas?

David Margolin

Evaluation of the current recommendations on repeat colonoscopy for colorectal cancer screening

David Margolin

Collaboration between Dx Biosamples and Department of Colon and Rectal Surgery at Ochsner – multiple projects

David Margolin

A Pilot, Prospective, Randomized, Controlled, Multicenter Technical Feasibility Clinical Study Comparing Standard Anastomosis Closure Technique to Standard Closure Techniques Plus Sylys® Surgical Sealant

David Margolin

Colorectal cancer screening in the elderly, is there a true age cut off? David Margolin

Efficacy and Safety of LifeSeal™ kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study

David Beck

Validation of an Automated System for Ostomy Output David Margolin

A Randomized Prospective Trial of the Impact of Low versus High Glycemic Index Supplements for Carbohydrate Loading in Colectomy

David Margolin

The Effects of Statins on Response to Neoadjuvant Radiotherapy in Rectal Cancer David Margolin

46

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

47

RESEARC

H

Gastroenterology Open Clinical Trials


CIS-USA-154 limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease and other gastrointestinal motility disorders

James Smith

The effectiveness and safety of modified needle knives in endoscopic mucosal resection of large sessile and flat lesions and early intramucosal malignancy of the gastrointestinal tract: a retrospective and prospective chart review

Nigel Girgrah

A prospective 3-year follow-up study in subjects previously treated in a phase IIb or phase III study with a TMC435-containing regimen for the treatment of hepatitis C virus (HCV) infection

Nigel Girgrah

A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of ustekinumab maintenance therapy in subjects with moderately to severely active Crohn’s disease (IMUNITI)

James Smith

A phase III, open-label trial of TMC435 in combination with peginterferon alpha-2a and ribavirin for HCV genotype-1 infected subjects who participated in the placebo group of a phase II/III TMC435 study (C201, C205, C206, C208, C216 or HPC3007), or who received short-term (up to 14 days) direct-acting antiviral treatment for hepatitis C infection in a selected Tibotec-sponsored phase I study

Nigel Girgrah

Domperidone in the relief of gastrointestinal disorders Arnab Ray

Demographics of Barrett’s esophagus in women: dysplasia, adenocarcinoma and other risk factors

James Smith

A multicenter, randomized, open-label, active-controlled trial to evaluate the safety and efficacy of Rifximin 550 mg with and without lactulose in subjects with a history of recurrent overt hepatic encephalopathy

Shobha Joshi

Expanded-access single named patient: daclatasvir (DCV) in combination with sofosbuvir (SOF) for the treatment of a patient with recurrent hepatitis C virus (HCV) infection

Shobha Joshi

A randomized, global, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of once-daily oral avatrombopag for the treatment of adults with thrombocytopenia associated with liver disease prior to an elective procedure

Shobha Joshi

A multicenter, double-blind, sponsor-open trial of IDN-6556 in subjects who had hepatitis C virus (HCV) reinfection and liver fibrosis following orthotopic liver transplantation for chronic HCV infection and who subsequently achieved a sustained virologic response following anti-HCV therapy

Shobha Joshi


Safety and clinical response after fecal microbiota transplantation in adults with mild to moderate ulcerative colitis

Arnab Ray

An observational study to assess documentation of hepatic encephalopathy in clinical practice

Shobha Joshi

A multicenter treatment protocol of daclatasvir (BMS-790052) in combination with sofosbuvir for the treatment of subjects with chronic hepatitis c and decompensated cirrhosis or post liver transplant subjects with chronic hepatitis c recurrence

Shobha Joshi

Improving endoscopic adherence to quality metrics in colonoscopy Sean Connolly

Prevalence of interval colorectal cancers at Ochsner Medical Center from 2011–2014 James Smith

A phase 3B randomized, open-label, multicenter trial assessing sofosbuvir + ribavirin for 16 or 24 weeks and sofosbuvir + pegylated interferon + ribavirin for 12 weeks in subjects with genotype 2 or 3 chronic HCV infection Gilead GS-US-334-0153

Natalie Bzowej

Multicenter, randomized phase 2B study to evaluate the efficacy, safety and tolerability of OCR-002 (ornithine phenylacetate) in hospitalized patients with cirrhosis and associated hyperammonemia with an episode of hepatic encephalopathy (STOP-HE study). protocol OCR002-HE209

Natalie Bzowej

Cystic mucin-producing pancreatic neoplasm in solid organ transplant recipients Natalie Bzowej

A phase 3, multicenter, open-label study to investigate the efficacy and safety of sofosbuvir/GS-5816 fixed-dose combination in subjects with chronic HCV infection and Child-Pugh class B cirrhosis

Natalie Bzowej

Chart review for a phase I, randomized, open-label, active-controlled, dose escalation study to evaluate the safety, tolerability, and immunogenicity of human hepatitis B virus (HBV) DNA plasmid (XXXX) alone or in combination with IL-12 DNA plasmid (YYYY) delivered IM followed by electroporation (EP) in entecavir-treated, HBeAg-positive, chronic genotype A and C hepatitis B patients

Natalie Bzowej

A multicenter, randomized, prospective, open-label phase III study to evaluate the efficacy, safety and pharmacokinetics of hepatitis C immune globulin intravenous (human) Civacir® in orthotopic liver transplant recipients

George Therapondos

Renal function outcomes in liver transplant recipients: the impact of ethnicity George Therapondos

Sarcopenia predicts poor recovery in liver transplant George Therapondos

48

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

49

RESEARC

H

PublicationsColon and Rectal Surgery

Dis Colon Rectum. 2016 Feb; 59(2): 140–7.doi:10.1097/DCR.0000000000000525. Current State of Colorectal Surgery Training: A Survey of Program Directors, Current and Recently Matched Colorectal Residents, and Recent Colorectal Graduates. Bailey MB1, Miller PA, Pawlak SE, Thomas MS, Beck DE, Vargas HD, Whitlow CB, Margolin DA.

Ochsner J. 2016 Winter; 16(4): 436–442. Perineural Liposomal Bupivacaine for Postoperative Pain Control in Patients Undergoing Upper Extremity Orthopedic Surgery: A Prospective and Randomized Pilot Study. Soberòn JR jr1, Ericson-Neilsen W1, Sisco-Wise LE2, Gustñaduy M3, Beck DE4.

Clin Colon Rectal Surg. 2016 June; 29(2): 138–44. Doi: 10.1055/s-0036-1580630. Management of Colorectal Anastomotic Leak. Thomas MS1, Margolin DA1.

J Gastrointest Surg. 2016 Dec; 20(12): 2035–2051. Epub 2016 Sep 16. Emerging Trends in the Etiology, Prevention, and Treatment of Gastrointestinal Anastomotic Leakage. Chadi SA1,2,3, Fingerhut A4,5, Berho M6, DEMeester SR7, Fleshman JW6, Hyman NH9, Margolin DA10, Martz JE11, McLemore EC12, Molena D13, Newman MI14, Rafferty JF15, Safar B16, Senagore AJ17, Zmora O18, Wexner SD19.

Bertoni DM, Hammond KL, Beck DE, Hicks TC, Whitlow CB, Vargas HD, Margolin DA. Use of sodium hyaluronate/carboxymethylcellulose bioresorbable membrane in loop ileostomy construction facilitates stoma closure. Ochsner J. 2017 Summer; 17(2): 146–149.

Sanabria-Salas MC, Hernández-Suárez G, Umaña-Pérez A, Rawlik K, Tenesa A, Serrano-López ML, Sánchez de Gómez M, Rojas MP, Bravo LE, Albis R, Plata JL, Green H, Borgovan T, Li L, Majumdar S, Garai J, Lee E, Ashktorab H, Brim H, Li L, Margolin D, Fejerman L, Zabaleta J. IL1B-CGTC haplotype is associated with colorectal cancer in admixed individuals with increased African ancestry. Sci Rep. 2017 Feb 3; 7: 41920.

Soberón JR Jr, Ericson-Neilsen W, Sisco-Wise LE, Gastañaduy M, Beck DE. Perineural liposomal bupivacaine for postoperative pain control in patients undergoing upper extremity orthopedic surgery: a prospective and randomized pilot study. Ochsner J. 2016 Winter; 16(4): 436–442.

Miller PE, Dao H, Paluvoi N, Bailey M, Margolin D, Shah N, Vargas HD. Comparison of 30-day postoperative outcomes after laparoscopic vs robotic colectomy. J Am Coll Surg. 2016 Aug; 223(2): 369–373. Epub 2016 Apr 19.

Chadi SA, Fingerhut A, Berho M, DeMeester SR, Fleshman JW, Hyman NH, Margolin DA, Martz JE, McLemore EC, Molena D, Newman MI, Rafferty JF, Safar B, Senagore AJ, Zmora O, Wexner SD. Emerging trends in the etiology, prevention, and treatment of gastrointestinal anastomotic leakage. J Gastrointest Surg. 2016 Dec; 20(12): 2035–2051. Epub 2016 Sep 16.

Gastroenterology

Janak Shah, MD

Gastrointest Endosc. 2016 Mar; 83(3): 638–42. doi: 10.1016/j.gie.2015.08.079. Underwater EMR of Adenomas of the Appendiceal Orifice (with Video). Binmoeller KF1, Hamerski CM1, Shah JN1, Bhat YM1, Kane SD1.

Gastrointest Endosc. 2016 June; 83(6): 1164–72. doi: 10.1016/j.gie.2015.09.040 Epub 2015 Oct 9. EUS-Guided Treatment of Gastric Fundal Varices with Combined Injection of Coils and Cyanoacrylate Glue: A Large U.S. Experience Over 6 Years (with Video). Bhat YM1, Weilert F1, Frederick RT1, Kane SD1, Shah JN1, Hamerski CM1, Binmoeller KF1.


Retrospective analysis of efficacy and safety of sorafenib in management of recurrent hepatocellular carcinoma in post liver transplant

George Therapondos

Observational, postmarketing renal safety surveillance registry in subjects with chronic hepatitis B virus (HBV) infection with decompensated liver disease receiving nucleotide/side therapy

George Therapondos

A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of ustekinumab induction therapy in subjects with moderately to severely active Crohn’s disease (UNITI-2)

James Smith

An open-label, phase 4 study of telaprevir, peginterferon alfa-2a (PEGASYS), and ribavirin (COPEGUS) in treatment-experienced Black/African American and non-Black/African American subjects with genotype 1 chronic hepatitis C virus who have not achieved a sustained viral response with a prior course of interferon-based therapy

Shobha Joshi

Non-interventional, prospective, cohort study of the effectiveness, safety, and utilization of two approved pegylated interferon-based direct-acting antiviral triple therapies in the management of genotype 1 chronic hepatitis C virus in routine clinical practice in the USA

Shobha Joshi

A phase 2 open-label clinical trial demonstrating the safety of RBX2660 microbiota suspension for the treatment of recurrent Clostridium difficile-associated diarrhea (CDAD)

Arnab Ray

A review of patients undergoing colonoscopy while on anti-thrombotic agents David Margolin

The Ochsner Experience with urinary bladder matrix in the treatment of complex fistula in ano

David Margolin

Morbidity and long-term mortality associated with ileostomy closure in rectal cancer patients before and after adjuvant therapy

David Margolin

Predictors of anastomotic biliary strictures in duct-to-duct liver transplant recipients Janak Shah; sub-PI: Ricardo Romero, George Therapondos and Humberto Bohorquez

Multicenter prospective study evaluating outcomes of digital single-operator peroral cholangioscopy

Janak Shah; sub-PI: Ricardo Romero

A multicenter prospective study evaluating outcomes of endoscopic eradication therapy in patients with Barrett’s esophagus-associated neoplasia (The TREAT-BE Consortium)

Ricardo Romero; sub-PI: Janak Shah

50

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

51

PUBLIC

ATIO

NS

Physician TeamColon and Rectal Surgery ProvidersCharles B. Whitlow, MD Chairman, Department of Colon

and Rectal SurgeryDavid E. Beck, MD Professor & Chairman Emeritus,

Colon and Rectal Surgery Ochsner Clinic School, University

of Queensland Medical Director, Revenue Cycle

and Operating Room Editor in Chief, Ochsner Journal Terry C. Hicks, MDWilliam (Forrest) Johnston, MDBrian R. Kann, MD Staff Surgeon and Associate

Residency Program Director, Colon and Rectal Surgery

David Margolin, MD Director of Research, Colon and

Rectal SurgeryH. David Vargas, MD Medical Director, Endoscopy Staff Surgeon and Residency Program

Director, Colon and Rectal SurgeryPeggy A. Alexander, NP Nurse Practitioner, Colon and

Rectal SurgeryBonnie Alvey, APRN Certified Wound and Ostomy Care Victoria Taullie, NP

General GastroenterologyArnab Ray, MD Section HeadSean Connolly, MD Director, Gastroenterology and

Hepatology Fellowship ProgramMatthew Rice, MDJames W. Smith, MD Austin Thomas, MDTrenise Martinez, PA Amanda Gutierrez, NPTiffany Tunnell, APRN

Advanced EndoscopyJanak Shah, MD Vice-Chairman, GastroenterologyAbdul El Chafic, MDJohn Evans, MDRicardo Romero, MD

Motility DisordersMonik Kowalczyk Lammi, MD Medical Director, Motility

Inflammatory Bowel DiseaseShamita B. Shah, MD Medical Director, Inflammatory Bowel

Disease ProgramKim Guidry, NP

HepatologyNigel Girgrah, MD, PhD Chairman, Department of

Gastroenterology and Hepatology Medical Director, Multi-Organ Transplant Institute

Cristal Brown, MDNatalie Bzowej, MD, PhD Director, Transplant Clinical ResearchGeorge Therapondos, MD, MPH Section Head, Hepatology and

Transplant Hepatology Medical Director, Living Donor Liver Transplant

Shobha Joshi, MD Director, Hepatology ResearchNyan Latt, MDAlicia Debautte, NPJamie Juckett, PASusan Martinez, NPJennifer Scheuermann, PAKristen Stevens, NPTara Labiche, PA

For patient referral and transfer information, please see page 54.

J Clin Gastroenterol. 2016 Aug; 50(7): 538–44. doi: 10.1097/MCG.0000000000000434. The Clinical Utility of Evaluating the Luminal Upper Gastrointestinal Tract During Linear Endoscopic Ultrasonography. Kim S1, Hamerski C, Ghassemi K, Shah J, Bhat Y, Klapman J, Komanduri S, Keswani RN, Bidari K, Wani S, Watson RR, Muthusamy VR.

Gastrointest Endosc. 2016 Apr; 83(4): 699–707. doi: 10.1016/j.gie.2015.10.020 Epub 2015 Oct 26. EUS-Guided Drainage of Peripancreatic Fluid Collections and Necrosis by Using a Novel Lumen-apposing Stent: A Large Retrospective, Multicenter U.S. Experience (with Videos). Siddiqui AA1, Adler DG2, Nieto J3, Shah JN4, Binmoeller KF4, Kane S4, Yan L1, Laique SN1, Kowalski T1, Loren DE1, Taylor LJ2, Munigala S5, Bhat YM4.

Gastrointest Endosc. 2016 Jun; 83(6): 1248–57. doi: 10.1016/j.gie.2015.11.014. Epub 2015 Dec 1. Endoscopic Resection is Cost-Effective Compared with Laparoscopic Resection in the Management of Complex Colon Polyps: An Economic Analysis. Law R1, Das A2, Gregory D1, Komanduri S1, Muthusamy R3, Rastogi A4, Vargo J5, Wallace MB6, Raju GS7, Mounzer R8, Klapman J9, Shah J10, Watson R3, Wilson R8, Edmundowicz SA11, Wani S8.

Endosc Int Open. 2016 Mar; 4(3): E263–75. doi: 10.1055/s-0042-100194. Epub 2016 Feb 4. The Efficacy of Peroral Cholangioscopy for Difficult Bile Duct Stones and Indeterminate Strictures: A Systematic Review and Meta-Analysis. Korrapati P1, Ciolino J1, Wani S2, Shah J3, Watson R4, Muthusamy VR4, Klapman J5, Komanduri S1.

Endosc Int Open. 2016 Mar; 4(3): E276-81. doi: 10.1055/s-0042-101789. Endoscopic Ultrasound-Guided Gastrojejunostomy with a Lumen-Apposing Metal Stent: A Multicenter, International Experience. Tyberg A1, Perez-Miranda M2, Sanchez-Ocaña R2, Peñas I2, de la Serna C2, Shah J3, Binmoeller K3, Gaidhane M1, Grimm I4, Baron T4, Kahaleh M1.

Gastrointest Endosc. 2016 Nov; 84(5): 764–769. doi: 10.1016/ j.gie.2016.03.1485. Epub 2016 Mar 31. Feasibility of Nonradiation EUS-Based ERCP in Patients with Uncomplicated Choledocholithiasis (with Video). Shah JN1, Bhat YM1, Hamerski CM1, Kane SD1, Binmoeller KF1.

Endosc Int Open. 2016 May; 4(5): E497–505. doi: 10.1055/ s-0042-106958. A Randomized Controlled Cross-Over Trial and Cost Analysis Comparing Endoscopic Ultrasound Fine Needle Aspiration and Fine Needle Biopsy. Aadam AA1, Wani S2, Amick A1, Shah JN3, Bhat YM3, Hamerski CM3, Klapman JB4, Muthusamy VR5, Watson RR5, Rademaker AW5, Keswani RN5, Keefer L1, Das A7, Komanduri S1.

Endosc Int Open. 2016 Sep; 4(9): E941–6. doi: 10.1055/s-0042-110789. Epub 2016 Aug 10. Wide Disparities in Attitudes and Practices Regarding Type II Sphincter of Oddi Dysfunction: A Survey of Expert U.S. Endoscopists. Watson RR1, Klapman J2, Komanduri S3, Shah JN4, Wani S5, Muthusamy R1.

Arnab Ray, MD

Future Microbiol. 2016 May; 11: 611–6. doi: 10.2217/fmb.16.10. Epub 2016 Mar 17. Does the Donor Matter? Donor vs Patient Effects in the Outcome of a Next-Generation Microbiota- Based Drug Trial for Recurrent Clostridium Difficile Infection. Ray A1, Jones C2.

Clin Infect Dis. 2016 Mar 1; 62(5): 596–602. doi: 10.1093/cid/civ938. Epub 2015 Nov 12. Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium Difficile Infection: Results of the PUNCH CD Study. Orenstein R1, Dubberke E2, Hardi R3, Ray A4, Mullane K5, Pardi DS6, Ramesh MS7, PUNCH CD Investigators.

Austin Thomas, MD

Ochsner J. 2016 Spring; 16(1): 90–5. Using Computerized Physician Order Entry to Ensure Appropriate Vaccination of Patients with Inflammatory Bowel Disease. Karr JR1, Lu JJ2, Smith RB1, Thomas AC1.

52

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

53

PHYSIC

IAN

TEAM

Patient referrals, transfers and consults are critically important. We make it easy for referring providers and their staff. To refer your patient for a clinic appointment, call our Clinic Concierge at 855.312.4190. To initiate a transfer to any Ochsner hospital, call our Regional Referral Center, staffed 24/7 by clinicians, at 855.OHS.LINK (647.5465).

For patients needing to schedule their own appointments, please call 866.OCHSNER (624.7637).

Ochsner Medical Center

1514 Jefferson Highway Jefferson, LA 70121

Visit us online at ochsner.org

About Ochsner Health SystemOchsner Health System is Louisiana’s largest non-profit, academic healthcare system. Driven by a mission to Serve, Heal, Lead, Educate and Innovate, coordinated clinical and hospital patient care is provided across the region by Ochsner’s 29 owned, managed and affiliated hospitals and more than 80 health centers and urgent care centers. Ochsner is the only Louisiana hospital recognized by U.S. News & World Report as a “Best Hospital” across four specialty categories caring for patients from all 50 states and more than 80 countries worldwide each year. Ochsner employs more than 18,000 employees and over 1,100 physicians in over 90 medical specialties and subspecialties, and conducts more than 600 clinical research studies. Ochsner Health System is proud to be a tobacco-free environment. For more information, please visit ochsner.org and follow us on Twitter and Facebook.

54

OC

HSN

ERO

UTC

OM

ES |

DIG

ESTI

VE

DIS

EASE

S

OC

HSN

ER.O

RG

OCHSNER OUTCOMES - Ochsner Health System...Ochsner Health System ... OUTCOMES DIGESTIVE DISEASES 7...

Documents

Transcript of OCHSNER OUTCOMES - Ochsner Health System...Ochsner Health System ... OUTCOMES DIGESTIVE DISEASES 7...